In fact, in the context of treating B cell lymphomas, PLCγ2 ibrutinib resistant variants are hyper-sensitive to activation regardless of BTK’s kinase activity suggesting that the kinase-independent functions of BTK might be responsible (Wist et al., 2020). The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.